Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. HANSEATISCHE WERTPAPIERBOERSE HAMBURG
  5. Sangui Biotech International, Inc.
  6. News
  7. Summary
    SBH   US80105B1017

SANGUI BIOTECH INTERNATIONAL, INC.

(SBH)
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021

09/28/2021 | 02:37pm EST

Sangui Biotech International, Inc. announced earnings results for the full year ended June 30, 2021. For the full year, the company announced operating loss was USD 151,138 compared to USD 181,394 a year ago. Net loss was USD 198,890 compared to USD 192,741 a year ago.


© S&P Capital IQ 2021
All news about SANGUI BIOTECH INTERNATIONAL, INC.
2021SANGUI BIOTECH INTERNATIONAL INC. : - Sales of USD 18,560 in first quarter - Reduction of ..
EQ
2021SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Con..
AQ
2021Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended..
CI
2021SANGUI BIOTECH INTERNATIONAL INC. : Granulox is awarded the prestigious Prix Galien
EQ
2021SANGUI BIOTECH INTERNATIONAL INC. : - Sales of USD 65,582 in fiscal year 2021 - Reduction ..
EQ
2021SANGUI BIOTECH INTERNATIONAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
2021Sangui Biotech International, Inc. Reports Earnings Results for the Full Year Ended Jun..
CI
2021SANGUI BIOTECH INTERNATIONAL INC. : - Granulox(R) - Follow up
EQ
2021SANGUI BIOTECH INTERNATIONAL INC. : - Significant increase in sales in the first nine mont..
EQ
2021SANGUI BIOTECH INTERNATIONAL : Management's Discussion and Analysis of Financial Condition..
AQ
More news
Financials (USD)
Sales 2021 0,07 M - -
Net income 2021 -0,20 M - -
Net Debt 2021 0,79 M - -
P/E ratio 2021 -21,6x
Yield 2021 -
Capitalization 3,80 M 3,78 M -
EV / Sales 2020 134x
EV / Sales 2021 90,6x
Nbr of Employees -
Free-Float 77,5%
Chart SANGUI BIOTECH INTERNATIONAL, INC.
Duration : Period :
Sangui Biotech International, Inc. Technical Analysis Chart | SBH | US80105B1017 | MarketScreener
Income Statement Evolution
Managers and Directors
Thomas Striepe President, CEO, CFO & Director
Hubertus Schmelz Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SANGUI BIOTECH INTERNATIONAL, INC.14.29%4
MODERNA, INC.-26.53%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707